Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10246) 10246
Book Review (1921) 1921
Publication (1256) 1256
Book Chapter (71) 71
Conference Proceeding (50) 50
Dissertation (27) 27
Archival Material (1) 1
Government Document (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7221) 7221
humans (6587) 6587
braf (5193) 5193
oncology (3983) 3983
mutation (3889) 3889
cancer (3268) 3268
female (3200) 3200
proto-oncogene proteins b-raf - genetics (3033) 3033
melanoma (3014) 3014
male (2988) 2988
middle aged (2516) 2516
aged (2063) 2063
braf mutation (2058) 2058
adult (2029) 2029
tumors (1686) 1686
pathology (1625) 1625
genetic aspects (1503) 1503
braf mutations (1445) 1445
prognosis (1346) 1346
colorectal cancer (1290) 1290
metastasis (1230) 1230
gene mutations (1215) 1215
melanoma - genetics (1202) 1202
mutations (1184) 1184
carcinoma (1114) 1114
vemurafenib (1089) 1089
metastatic melanoma (1074) 1074
kras (1054) 1054
analysis (1044) 1044
research (1042) 1042
animals (1040) 1040
cell biology (1032) 1032
aged, 80 and over (1020) 1020
survival (996) 996
melanoma - pathology (986) 986
expression (973) 973
thyroid neoplasms - genetics (961) 961
neoplasms (944) 944
care and treatment (932) 932
immunohistochemistry (928) 928
microsatellite instability (918) 918
melanoma - drug therapy (914) 914
colorectal neoplasms - genetics (909) 909
thyroid cancer (908) 908
cell line, tumor (906) 906
article (846) 846
thyroid neoplasms - pathology (822) 822
dna mutational analysis (801) 801
dermatology (767) 767
proto-oncogene proteins b-raf - metabolism (735) 735
diagnosis (724) 724
kinases (721) 721
chemotherapy (715) 715
surgery (695) 695
activation (686) 686
braf v600e mutation (678) 678
proto-oncogene proteins b-raf - antagonists & inhibitors (670) 670
antineoplastic agents - therapeutic use (663) 663
colorectal neoplasms - pathology (662) 662
young adult (659) 659
health aspects (657) 657
endocrinology & metabolism (655) 655
gene (651) 651
biomarkers, tumor - genetics (639) 639
medicine & public health (629) 629
skin neoplasms - pathology (622) 622
skin neoplasms - genetics (618) 618
ras proteins - genetics (602) 602
pathway (596) 596
resistance (588) 588
digestive system diseases (586) 586
b-raf (585) 585
mutation - genetics (582) 582
therapy (580) 580
adolescent (578) 578
mice (570) 570
malignant-melanoma (567) 567
open-label (563) 563
colon-cancer (557) 557
retrospective studies (557) 557
biochemistry & molecular biology (542) 542
signal transduction (540) 540
abridged index medicus (530) 530
development and progression (527) 527
gene expression (524) 524
patients (519) 519
proteins (519) 519
neoplasm staging (511) 511
dna methylation (506) 506
treatment outcome (503) 503
genes (499) 499
proto-oncogene proteins - genetics (498) 498
medicine, research & experimental (492) 492
acquired-resistance (490) 490
targeted therapy (487) 487
immunotherapy (486) 486
papillary thyroid carcinoma (483) 483
inhibition (471) 471
phenotype (471) 471
melanoma - metabolism (465) 465
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10028) 10028
French (95) 95
German (95) 95
Spanish (34) 34
Korean (27) 27
Russian (22) 22
Chinese (10) 10
Polish (10) 10
Japanese (8) 8
Czech (5) 5
Portuguese (5) 5
Hungarian (4) 4
Italian (2) 2
Turkish (2) 2
Croatian (1) 1
Persian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract—A study of 24 cases from the Netherlands
by van Engen-van Grunsven, Adriana C.H and Küsters-Vandevelde, Heidi V.N and De Hullu, Joanne and van Duijn, Lucette M and Rijntjes, Jos and Bovée, Judith V.M.G and Groenen, Patricia J.T.A and Blokx, Willeke A.M
Gynecologic Oncology, ISSN 0090-8258, 2014, Volume 134, Issue 1, pp. 10 - 14
Abstract Objective The aim of this study was to evaluate a series of primary melanomas of the female urogenital tract for oncogenic mutations in KIT , NRAS and... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | MAPK pathway | Vaginal melanoma | NRAS | BRAF | Urogenital tract melanoma | KIT | N-RAS MUTATIONS | GENE-MUTATIONS | COMPLETE RESPONSE | OPEN-LABEL | OBSTETRICS & GYNECOLOGY | HUMAN CUTANEOUS MELANOMA | METASTATIC MELANOMA | MUCOSAL MELANOMA | ONCOLOGY | BRAF MUTATIONS | EXPRESSION | IMATINIB MESYLATE | Melanoma - epidemiology | Exons | Humans | Middle Aged | Netherlands - epidemiology | Melanoma - enzymology | Genital Neoplasms, Female - epidemiology | Formaldehyde | MAP Kinase Signaling System | Paraffin Embedding | Melanoma - genetics | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Genital Neoplasms, Female - enzymology | Retrospective Studies | Tissue Fixation | Genital Neoplasms, Female - genetics | Membrane Proteins - genetics | Ureteral Neoplasms - genetics | Molecular Epidemiology | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Genetic aspects | Melanoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Mutation‐specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas
by Sinicrope, Frank A and Smyrk, Thomas C and Tougeron, David and Thibodeau, Stephen N and Singh, Shalini and Muranyi, Andrea and Shanmugam, Kandavel and Grogan, Thomas M and Alberts, Steven R and Shi, Qian
Cancer, ISSN 0008-543X, 08/2013, Volume 119, Issue 15, pp. 2765 - 2770
Immunohistochemical analysis of mutant (substitution of valine by glutamic acid at position 600 [V600E]) v‐Raf murine sarcoma viral oncogene homolog B1 (BRAF)... 
V600E | mutation | microsatellite instability | colon cancer | protein | BRAF | immunohistochemistry | Colonic Neoplasms - genetics | Microsatellite Instability | Prognosis | Prospective Studies | Antibodies - chemistry | Humans | Middle Aged | Male | Immunohistochemistry - methods | Point Mutation | Proto-Oncogene Proteins B-raf - biosynthesis | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Antibodies - genetics | Female | Aged | Biomarkers, Tumor - genetics | Colonic Neoplasms - enzymology | Neoplasm Staging | Biomarkers, Tumor - biosynthesis | Care and treatment | Colon cancer | Gene mutations | Patient outcomes | Physiological aspects | Genetic aspects | Research | Diagnosis | Gene expression | Index Medicus | Abridged Index Medicus | MSI | BRAFV600E mutation | BRAFV600E protein
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation
by Kadota, Kyuichi and Yeh, Yi-Chen and D’Angelo, Sandra P and Moreira, Andre L and Kuk, Deborah and Sima, Camelia S and Riely, Gregory J and Arcila, Maria E and Kris, Mark G and Rusch, Valerie W and Adusumilli, Prasad S and Travis, William D
The American Journal of Surgical Pathology, ISSN 0147-5185, 08/2014, Volume 38, Issue 8, pp. 1118 - 1127
Multiple reports indicate that epidermal growth factor receptor (EGFR) mutations are associated with lepidic-pattern lung adenocarcinoma and that KRAS... 
mutation | adenocarcinoma | subtype | Lung | mucin | GENE-MUTATIONS | SURGERY | EGFR MUTATIONS | PATHOLOGY | lung | GROWTH-FACTOR RECEPTOR | GRADING SYSTEM | BRAF MUTATIONS | INTERNATIONAL-ASSOCIATION | BRONCHIOLOALVEOLAR PATHOLOGICAL SUBTYPE | ATYPICAL ADENOMATOUS HYPERPLASIA | ROUTINE-PRACTICE | CLINICOPATHOLOGICAL FEATURES | Immunohistochemistry | ras Proteins - genetics | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Adenocarcinoma, Mucinous - pathology | Tissue Array Analysis | Humans | Lung Neoplasms - metabolism | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Young Adult | Adenocarcinoma - metabolism | DNA Mutational Analysis | Mucins - metabolism | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Adenocarcinoma, Mucinous - metabolism | Aged | Adenocarcinoma, Mucinous - genetics | Mutation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification
by Gierke, Midea and Sperveslage, Jan and Schwab, David and Beschorner, Rudi and Ebinger, Martin and Schuhmann, Martin U and Schittenhelm, Jens
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 1/2016, Volume 142, Issue 1, pp. 89 - 100
Gliomas are the leading cause of cancer-related morbidity in children and comprise a clinical, histological and molecular heterogenous group of CNS tumors.... 
BRAF V600E | Medicine & Public Health | Hematology | Glioma | IDH1 | Classification | KIAA1549 – BRAF | Oncology | Cancer Research | Internal Medicine | KIAA1549–BRAF | KIAA1549-BRAF | ACTIVATION | DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS | CHRONIC EPILEPSY | IDH1 MUTATIONS | ADULTS | LOW-GRADE GLIOMAS | DIFFUSE GLIOMAS | BRAF(V600E) MUTATION | PILOCYTIC ASTROCYTOMAS | GENE | ONCOLOGY | Oncogene Proteins, Fusion - metabolism | Prognosis | Follow-Up Studies | Tissue Array Analysis | Humans | Middle Aged | Child, Preschool | Infant | Male | Immunoenzyme Techniques | Young Adult | Polymerase Chain Reaction | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Child | Infant, Newborn | Proto-Oncogene Proteins B-raf - metabolism | Central Nervous System Neoplasms - classification | Central Nervous System Neoplasms - genetics | Isocitrate Dehydrogenase - genetics | Mutation - genetics | Central Nervous System Neoplasms - pathology | Oncogene Proteins, Fusion - genetics | Proto-Oncogene Proteins B-raf - genetics | Adolescent | Isocitrate Dehydrogenase - metabolism | Aged | Biomarkers, Tumor - genetics | Neoplasm Staging | Immunohistochemistry | Pediatrics | Genetic aspects | Gene mutations | Gliomas | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
by Capper, David and Preusser, Matthias and Habel, Antje and Sahm, Felix and Ackermann, Ulrike and Schindler, Genevieve and Pusch, Stefan and Mechtersheimer, Gunhild and Zentgraf, Hanswalter and von Deimling, Andreas
Acta Neuropathologica, ISSN 0001-6322, 7/2011, Volume 122, Issue 1, pp. 11 - 19
Activating mutations of the serine threonine kinase v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) are frequent in benign and malignant human tumors and... 
V600E | Immunohistochemistry | Pathology | Neurosciences | Biomarker | Medicine & Public Health | Melanoma | BRAF | Mutation | Monoclonal antibody | Papillary thyroid carcinoma | ACTIVATION | IDH1 ANTIBODY | PATHOLOGY | NEUROSCIENCES | CLINICAL NEUROLOGY | KRAS MUTATIONS | NRAS | INHIBITION | SIGNALING PATHWAY | THYROID-CARCINOMA | HIGH-FREQUENCY | B-RAF | Predictive Value of Tests | Thyroid Neoplasms - diagnosis | Melanoma - diagnosis | Prognosis | Humans | Brain Neoplasms - metabolism | Carcinoma, Papillary - metabolism | Brain Neoplasms - secondary | Biomarkers, Tumor - metabolism | Female | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Brain Neoplasms - diagnosis | Mice, Inbred C57BL | Mutation - genetics | Carcinoma, Papillary - pathology | Melanoma - secondary | Immunohistochemistry - methods | Antibodies, Monoclonal - genetics | Animals | Proto-Oncogene Proteins B-raf - genetics | Biomarkers, Tumor - genetics | Mice | Carcinoma, Papillary - diagnosis | Thyroid Neoplasms - metabolism | Thyroid Neoplasms - pathology | Medical colleges | Sarcoma | Oncology, Experimental | Thyroid diseases | Amino acids | Metastasis | Research | Gene mutations | Analysis | Monoclonal antibodies | Genetic aspects | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Detection of the BRAF V600E Mutation in Colon Carcinoma: Critical Evaluation of the Imunohistochemical Approach
by Lasota, Jerzy and Kowalik, Artur and Wasag, Bartosz and Wang, Zeng-Feng and Felisiak-Golabek, Anna and Coates, Tiffany and Kopczynski, Janusz and Gozdz, Stanislaw and Miettinen, Markku
The American Journal of Surgical Pathology, ISSN 0147-5185, 09/2014, Volume 38, Issue 9, pp. 1235 - 1241
Recently BRAF V600E mutant–specific antibody (clone VE1) became available to immunohistochemically pinpoint the occurrence of these BRAF-mutant proteins in... 
BRAF V600 allele-specific PCR | BRAF V600E | BRAF V600 qPCR | the Cobas 4800 BRAF V600 mutation test | colon cancer | immunohistochemistry | Sanger sequencing | SURGERY | VE1 | TUMOR-TISSUE | LYNCH SYNDROME | PATHOLOGY | METASTATIC COLORECTAL-CANCER | PITUITARY-ADENOMAS | MELANOMA | THERAPY | KRAS | EXPRESSION | Immunohistochemistry | Predictive Value of Tests | ras Proteins - genetics | Colonic Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | United States | Humans | Middle Aged | Male | DNA Mutational Analysis | DNA Mismatch Repair | Polymerase Chain Reaction | Poland | Adult | Female | Adenocarcinoma - genetics | Genetic Predisposition to Disease | Reproducibility of Results | Membrane Proteins - genetics | Adenocarcinoma - enzymology | Proto-Oncogene Proteins - genetics | Adenocarcinoma - secondary | Automation, Laboratory | Phenotype | Biopsy | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Colonic Neoplasms - enzymology | Mutation | Index Medicus | the cobas® 4800 BRAF V600 Mutation Test
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma
by Marimuthu, Adhirai and D'Andrea, Kurt and Lin, Paul S and Puzanov, Igor and Chapman, Paul B and Zhang, Jiazhong and Tsai, James and Ibrahim, Prabha N and Cho, Hanna and West, Brian L and Nathanson, Katherine L and Zhang, Kam Y. J and Zhang, Ying and Nolop, Keith and Schlessinger, Joseph and Grippo, Joseph and Shellooe, Rafe and Zhang, Chao and Flaherty, Keith T and Tsang, Garson and Powell, Ben and Kim, Kevin B and Wong, Bernice and Stumm, Michael and Ribas, Antoni and Spevak, Wayne and Higgins, Brian and Sosman, Jeffrey A and Artis, Dean R and Habets, Gaston and Hirth, Peter and Burton, Elizabeth A and Iyer, Raman and Su, Fei and Koehler, Astrid and Lee, Richard J and Bollag, Gideon and Nguyen, Hoa and McArthur, Grant A and Xu, Xiaowei
Nature, ISSN 0028-0836, 09/2010, Volume 467, Issue 7315, pp. 596 - 599
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the... 
ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | MUTATION | KERATOACANTHOMAS | SENSITIVITY | SENESCENCE | SORAFENIB | HUMAN CANCER | PROGRESSION | BRAF(V600E) | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Macaca fascicularis | Melanoma - enzymology | Substrate Specificity | Positron-Emission Tomography | Extracellular Signal-Regulated MAP Kinases - metabolism | Indoles - administration & dosage | Neoplasm Metastasis | Melanoma - genetics | Phosphorylation - drug effects | Mutant Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Sulfonamides - chemistry | Mutant Proteins - genetics | Models, Molecular | Rats | Mutant Proteins - metabolism | Melanoma - pathology | Mutation - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Indoles - adverse effects | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mutant Proteins - chemistry | Alleles | Dogs | Sulfonamides - adverse effects | Indoles - therapeutic use | Indoles - chemistry | Sulfonamides - administration & dosage | Control | Gene mutations | Melanoma | Development and progression | Genetic aspects | Research | Health aspects | Protein kinases | Cancer | Proteins | Mutation | Kinases | Rodents | Index Medicus | targeted therapy | melanoma | BRAF | PLX4032 | biomarker | oncogene
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
by Dummer, Reinhard, Prof and Schadendorf, Dirk, Prof and Ascierto, Paolo A, MD and Arance, Ana, MD and Dutriaux, Caroline, MD and Di Giacomo, Anna Maria, MD and Rutkowski, Piotr, Prof and Del Vecchio, Michele, MD and Gutzmer, Ralf, Prof and Mandala, Mario, MD and Thomas, Luc, Prof and Demidov, Lev, Prof and Garbe, Claus, Prof and Hogg, David, MD and Liszkay, Gabriella, Prof and Queirolo, Paola, MD and Wasserman, Ernesto, MD and Ford, James, MS and Weill, Marine, MSc and Sirulnik, L Andres, MD and Jehl, Valentine, MSc and Bozón, Viviana, MD and Long, Georgina V, Prof and Flaherty, Keith, MD
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 435 - 445
Summary Background There are no established therapies specific for NRAS -mutant melanoma despite the emergence of immunotherapy. We aimed to assess the... 
Hematology, Oncology and Palliative Medicine | DABRAFENIB | MEK INHIBITION | ONCOLOGY | IMPROVED SURVIVAL | SELUMETINIB | BRAF | MUTATIONS | DOCETAXEL | VEMURAFENIB | Dacarbazine - administration & dosage | Prognosis | Follow-Up Studies | Membrane Proteins - genetics | Humans | Middle Aged | Male | Survival Rate | Melanoma - pathology | Mutation - genetics | Benzimidazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Melanoma - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Hospitals | Sarcoma | Immunotherapy | Melanoma | Skin | Research institutes | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The BRAF(V)(600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
by Walczyk, A and Kowalska, A and Kowalik, A and Sygut, J and Wypiorkiewicz, E and Chodurska, R and Pieciak, L and Gozdz, S
CLINICAL ENDOCRINOLOGY, ISSN 0300-0664, 06/2014, Volume 80, Issue 6, pp. 899 - 904
Context An activating mutation in the gene BRAF has been correlated with poorer prognosis and more aggressive clinical course in papillary thyroid carcinoma... 
POPULATION | BRAF(V600E) MUTATION | PROGNOSTIC-FACTORS | ENDOCRINOLOGY & METABOLISM | BRAF V600E MUTATION | RISK | PATHOGENIC ROLE | CANCER | CARCINOMA | ASSOCIATION | FEATURES | Carcinoma, Papillary - genetics | Prognosis | Humans | Middle Aged | Male | Treatment Outcome | Lymphatic Metastasis | Incidence | Disease-Free Survival | Thyroid Neoplasms - genetics | Neoplasm Metastasis | Codon | Proto-Oncogene Proteins B-raf - genetics | Alleles | Female | Aged | Retrospective Studies | Mutation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: A prospective case series of 960 patients
by Kleiman, David A and Sporn, Matthew J and Beninato, Toni and Crowley, Michael J and Nguyen, Anvy and Uccelli, Alessia and Scognamiglio, Theresa and Zarnegar, Rasa and Fahey III, Thomas J
Cancer, ISSN 0008-543X, 04/2013, Volume 119, Issue 8, pp. 1495 - 1502
BACKGROUND: Preoperative B-type Raf kinase Val600Glu mutation, or BRAF(V600E), analysis has been proposed as a tool to guide initial surgery for indeterminate... 
thyroid nodule | fine-needle biopsy | thyroid neoplasms | BRAF(V600E) | DIAGNOSIS | NODE DISSECTION | BIOPSY SPECIMENS | PAPILLARY CARCINOMA | CANCER | FINE-NEEDLE-ASPIRATION | ONCOLOGY | BRAF MUTATION | ATYPIA | UNDETERMINED SIGNIFICANCE | BETHESDA SYSTEM | Thyroid Nodule - genetics | Genetic Testing | Prospective Studies | Early Detection of Cancer | Humans | Middle Aged | Risk Factors | Male | Biopsy, Fine-Needle | Proto-Oncogene Proteins B-raf - genetics | Thyroid Nodule - pathology | Cytological Techniques | Female | Thyroid Nodule - surgery | Usage | Care and treatment | Gene mutations | Thyroid diseases | Genetic aspects | Biopsy, Needle | Management | Diagnosis | Health aspects | Phosphotransferases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
by Liao, Xiaoyun and Lochhead, Paul and Nishihara, Reiko and Morikawa, Teppei and Kuchiba, Aya and Yamauchi, Mai and Imamura, Yu and Qian, Zhi Rong and Baba, Yoshifumi and Shima, Kaori and Sun, Ruifang and Nosho, Katsuhiko and Meyerhardt, Jeffrey A and Giovannucci, Edward and Fuchs, Charles S and Chan, Andrew T and Ogino, Shuji
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 17, pp. 1596 - 1606
In this study, mortality from colorectal cancer was reduced by about 80% in a subgroup of patients with tumors that expressed a mutated, activated form of... 
ISLAND METHYLATOR PHENOTYPE | COLON-CANCER | MEDICINE, GENERAL & INTERNAL | METASTASIS | INHIBITION | RANDOMIZED-TRIALS | BRAF MUTATION | MICROSATELLITE INSTABILITY | RISK | PERSONALIZED MEDICINE | MOLECULAR PATHOLOGICAL EPIDEMIOLOGY | Colorectal Neoplasms - mortality | Cyclooxygenase 2 Inhibitors - pharmacology | Colorectal Neoplasms - genetics | Humans | Middle Aged | Proportional Hazards Models | Male | Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases | Signal Transduction - drug effects | Colorectal Neoplasms - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Survival Analysis | Female | Aged | Aspirin - therapeutic use | Biomarkers, Tumor - genetics | Aspirin - pharmacology | Mutation | Drugs | Dose-response relationship (Biochemistry) | Aspirin | Gene mutations | Analysis | Colorectal cancer | Dosage and administration | Genetic aspects | Product/Service Evaluations | Research | Drug therapy | Oncogenes | Phenotypes | Tumor markers | Colorectal carcinoma | AKT protein | Microsatellite instability | Long interspersed nucleotide elements | Survival | Epidemiology | 1-Phosphatidylinositol 3-kinase | Prostaglandin endoperoxide synthase | Colon cancer | Rectum | DNA methylation | Death | Cyclooxygenase-2 | Diagnosis | Colon | Methylation | CpG islands | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
by Schindler, G and Capper, D and Meyer, J and Janzarik, W and Omran, H and Herold-Mende, C and Schmieder, K and Wesseling, P and Mawrin, C and Hasselblatt, M and Louis, D.N and Korshunov, A and Pfister, S and Hartmann, C and Paulus, W and Reifenberger, G and Deimling, A. Von
Acta Neuropathologica, ISSN 0001-6322, 2011, Volume 121, Issue 3, pp. 397 - 405
Missense mutations of the V600E type constitute the vast majority of tumor-associated somatic alterations in the v-RAF murine sarcoma viral oncogene homolog B1... 
Brain tumor | Pathology | Neurosciences | Ganglioglioma | V600E mutation | Medicine & Public Health | BRAF | Pleomorphic xanthoastrocytoma | GLIOMAS | B-RAF GENE | PATHOLOGY | CANCER | NEUROSCIENCES | CLINICAL NEUROLOGY | PATHWAY ACTIVATION | ATYPICAL TERATOID/RHABDOID TUMOR | COMPONENT | DUPLICATION | INHIBITOR | MAPK PATHWAY | EXPRESSION | Astrocytoma - genetics | Gene Frequency - genetics | World Health Organization | Signal Transduction | Humans | Brain Neoplasms - pathology | Brain Neoplasms - genetics | Child, Preschool | Exons - genetics | Mutation, Missense - genetics | Young Adult | Ganglioglioma - genetics | Astrocytoma - pathology | Proto-Oncogene Proteins B-raf - genetics | Ganglioglioma - pathology | Adolescent | Adult | Nervous System Neoplasms - genetics | Retrospective Studies | Child | Nervous System Neoplasms - pathology | Medical colleges | Molecular genetics | Sarcoma | Neurons | Brain tumors | Oncology, Experimental | Melanoma | Thyroid diseases | Research | Codon | Gene mutations | Gliomas | Analysis | Genetic research | Genetic aspects | Cancer | Index Medicus | meningioma | Pediatrics | Exons | Glioblastoma | Clinical trials | Insertion | Adenoma | Neuronal-glial interactions | Missense mutation | Sheaths | Colon | Astrocytoma | Oncogenes | Peripheral nervous system | Astrocytes | Base pairs | Central nervous system diseases | Glioma | Pituitary | Codons | papillary thyroid carcinoma | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights